US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo

The US FDA approved on August 17 an application for the novel treatment for malignant melanoma vemurafenib (brand name in the US: Zelboraf) filed by F. Hoffmann-La Roche. Discovered by Plexxikon of the US, a member of the Daiichi Sankyo...read more